CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
– EBITDA grew 47% for 12 months ended 31 Dec 2021– Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN’s shareholder value– Growth trend in revenue expected to […]